Cargando…

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

BACKGROUND: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy. METHODS: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Shuangping, Li, Xia, Rohr, Joseph, Wang, Yingmei, Ma, Shirong, Chen, Peng, Wang, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845361/
https://www.ncbi.nlm.nih.gov/pubmed/27113214
http://dx.doi.org/10.1186/s13000-016-0491-5
_version_ 1782428928339607552
author Guo, Shuangping
Li, Xia
Rohr, Joseph
Wang, Yingmei
Ma, Shirong
Chen, Peng
Wang, Zhe
author_facet Guo, Shuangping
Li, Xia
Rohr, Joseph
Wang, Yingmei
Ma, Shirong
Chen, Peng
Wang, Zhe
author_sort Guo, Shuangping
collection PubMed
description BACKGROUND: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy. METHODS: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasive breast carcinomas with four distinct immunophenotypes and in association with clinicopathological features. RESULTS: Of these cases, 138 (61.1 %) were defined as EZH2-overexpressing with a multiplicative score > 3. EZH2 expression was inversely related to the status of ER and PR (Chi-square, p < 0.001), and it was significantly associated with HER2 positivity, high proliferative index, and high histologic grade (Chi-square, p < 0.05). ER-positive breast carcinoma with low proliferative index (Ki67 < 14 %) showed the lowest expression and triple-negative breast carcinoma showed the highest overexpression of EZH2, 18.5 % (10/54) versus 90.9 % (50/55) (Chi-square, p < 0.001). Intriguingly, 88 % (44/50) cases of grade 3 triple-negative breast carcinoma showed uniformly strong EZH2 expression with a multiplicative score of 9. The percentage of EZH2 overexpression in ER-positive breast carcinoma with a high proliferative index or HER2-positive cases were 61.2 and 74 %, respectively. Furthermore, EZH2 expression was significantly elevated in high-grade DCIS compared to benign lesions (90 % versus 0, p < 0.001). However, there is no association between EZH2 expression and the status of histone 3 lysine 27 trimethylation or other clinicopathologic features. CONCLUSION: In summary, triple-negative breast carcinoma showed the highest overexpression of EZH2. EZH2 overexpression is associated aggressive pathologic features including high nuclear grade, high proliferative index, and positivity of HER2 of breast carcinoma.
format Online
Article
Text
id pubmed-4845361
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48453612016-04-27 EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features Guo, Shuangping Li, Xia Rohr, Joseph Wang, Yingmei Ma, Shirong Chen, Peng Wang, Zhe Diagn Pathol Research BACKGROUND: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy. METHODS: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasive breast carcinomas with four distinct immunophenotypes and in association with clinicopathological features. RESULTS: Of these cases, 138 (61.1 %) were defined as EZH2-overexpressing with a multiplicative score > 3. EZH2 expression was inversely related to the status of ER and PR (Chi-square, p < 0.001), and it was significantly associated with HER2 positivity, high proliferative index, and high histologic grade (Chi-square, p < 0.05). ER-positive breast carcinoma with low proliferative index (Ki67 < 14 %) showed the lowest expression and triple-negative breast carcinoma showed the highest overexpression of EZH2, 18.5 % (10/54) versus 90.9 % (50/55) (Chi-square, p < 0.001). Intriguingly, 88 % (44/50) cases of grade 3 triple-negative breast carcinoma showed uniformly strong EZH2 expression with a multiplicative score of 9. The percentage of EZH2 overexpression in ER-positive breast carcinoma with a high proliferative index or HER2-positive cases were 61.2 and 74 %, respectively. Furthermore, EZH2 expression was significantly elevated in high-grade DCIS compared to benign lesions (90 % versus 0, p < 0.001). However, there is no association between EZH2 expression and the status of histone 3 lysine 27 trimethylation or other clinicopathologic features. CONCLUSION: In summary, triple-negative breast carcinoma showed the highest overexpression of EZH2. EZH2 overexpression is associated aggressive pathologic features including high nuclear grade, high proliferative index, and positivity of HER2 of breast carcinoma. BioMed Central 2016-04-26 /pmc/articles/PMC4845361/ /pubmed/27113214 http://dx.doi.org/10.1186/s13000-016-0491-5 Text en © Guo et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Guo, Shuangping
Li, Xia
Rohr, Joseph
Wang, Yingmei
Ma, Shirong
Chen, Peng
Wang, Zhe
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title_full EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title_fullStr EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title_full_unstemmed EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title_short EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
title_sort ezh2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845361/
https://www.ncbi.nlm.nih.gov/pubmed/27113214
http://dx.doi.org/10.1186/s13000-016-0491-5
work_keys_str_mv AT guoshuangping ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT lixia ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT rohrjoseph ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT wangyingmei ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT mashirong ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT chenpeng ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures
AT wangzhe ezh2overexpressionindifferentimmunophenotypesofbreastcarcinomaandassociationwithclinicopathologicfeatures